Peter Laing
Nessuna posizione attualmente
Profilo
Peter Laing has been Chief Operating Officer of Lipoxen Plc since August 18, 2008.
He joined Lipoxen in March 2002.
Dr. Laing joined Peptide Therapeutics as a Director of Research.
He is Non-Executive Chairman of Activotec Ltd.
Dr. Laing held key executive positions at Actinova Ltd.
and Syngenix Ltd.
He was a Non-Executive Director of Adjuvantix Ltd.
Precedenti posizioni note di Peter Laing
| Società | Posizione | Fine |
|---|---|---|
Xenetic Biosciences (UK) Ltd.
 Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Direttore operativo | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Peter Laing
